| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.162.040 | 1.626.647 | 1.830.949 | 1.813.873 | 1.933.420 | 2.123.730 | 2.173.511 | - | - | - |
| Total Income - EUR | 1.163.837 | 1.629.925 | 1.834.445 | 1.816.836 | 1.935.913 | 2.127.612 | 2.175.197 | - | - | - |
| Total Expenses - EUR | 1.068.628 | 1.577.978 | 1.681.684 | 1.682.260 | 1.798.676 | 1.950.846 | 2.138.754 | - | - | - |
| Gross Profit/Loss - EUR | 95.209 | 51.948 | 152.761 | 134.577 | 137.237 | 176.766 | 36.443 | - | - | - |
| Net Profit/Loss - EUR | 89.453 | 43.636 | 150.865 | 109.380 | 117.200 | 156.458 | 27.612 | - | - | - |
| Employees | 10 | 14 | 13 | 12 | 13 | 13 | 13 | - | - | - |
Check the financial reports for the company - Diana Pharmax S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 81.287 | 73.707 | 112.305 | 100.140 | 117.224 | 99.153 | 83.512 | - | - | - |
| Current Assets | 458.524 | 950.575 | 768.414 | 1.069.246 | 961.873 | 1.350.699 | 1.668.788 | - | - | - |
| Inventories | 119.629 | 142.280 | 217.970 | 264.368 | 324.850 | 432.492 | 371.843 | - | - | - |
| Receivables | 304.444 | 719.631 | 494.110 | 795.080 | 634.642 | 911.466 | 1.234.191 | - | - | - |
| Cash | 34.452 | 88.664 | 56.334 | 9.798 | 2.380 | 6.741 | 62.754 | - | - | - |
| Shareholders Funds | 190.079 | 231.776 | 378.719 | 431.724 | 530.027 | 676.437 | 689.047 | - | - | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | - | - | - |
| Debts | 349.733 | 792.505 | 502.116 | 737.933 | 549.434 | 773.564 | 1.063.512 | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Diana Pharmax S.r.l.